Michiko Taniguchi, PhD

Michiko Taniguchi, PhD

Assistant Professor, Pathology and Immunology

Additional Titles

Associate Director, Barnes-Jewish Hospital HLA Laboratory

Education

  • B.App.Sc., Medical Laboratory Sciences, Royal Melbourne Institute of Technology (RMIT University), Australia
  • MS, Molecular Microbiology and Immunology, University of Southern California, Los Angeles CA
  • Ph.D, Medical Sciences, Kobe University, Japan

Board Certifications

  • American Board of Histocompatibility Immunogenetics (ABHI)
  • Certified Histocompatibility Specialist (ABHI)

Recognition

  • Poster Distinction Award: American Transplant Congress (ATC), 2010
  • Young Innovator Award: American Society of Transplantation (AST), 2010
  • Best Visual Poster Award American Society for Histocompatibility and Immunogenetics (ASHI) Annual Meeting, 2011
  • Poster Distinction Award, ASHI Annual Meeting, 2012
  • Best Visual Poster Award, ASHI Annual Meeting, 2012
  • Most Innovative Poster Award, ASHI Annual Meeting, 2015

Clinical Interests

  • HLA and non-HLA antibodies in transplantation
  • Laboratory information system and automation

Research Interests

  • HLA epitope matching in transplantation
  • Impact of HLA expression in transplantation
  • Improving lab data management

Publications

Peton, B, Taniguchi, M, Magiola, M, Al Malki, MM, Gendzekhadze, K. Specificity of HLA monoclonal antibodies and their use to determine HLA expression on lymphocytes and peripheral blood stem cells. HLA. 2023; 1-12
Peton, B, Taniguchi, M, Garcia-Gomez, JF, Zeng, B, Oki, A, Banuelos, N, Abou-Taleb, R, Al Malki, MM, Gendzekhadze, K. Identification of a novel HLA-A24 null allele and evaluation of its cell-surface expression on lymphocytes. Transplantation. 2022;106(6):312–313.
Carter, M, Taniguchi, M, Yang, D, Arslan, S, Shouse, G, Ali, H, Karras, N, Gendzekhadze, K, Al Malki, MM. Donor-specific HLA antibodies associate with chronic graft-versus-host disease in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2021;57:134–136.
Ciurea, SO, Al Malki, MM, Kongtim, P, Zou, J, Aung, FM, Rondon, G, Chen, J, Taniguchi, M, Otoukesh, S, Nademanee, A, Forman ,SJ, Champlin, R, Gendzekhadze, K, Cao, K. Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv, 2021. 5(20): p. 4031-4043.
Ohe, H, Uchida, Y, Yoshizawa, A, Hirano, H, Taniguchi, M, Maruya, E, Yurugi, K, Hishida, R, Maekawa, T, Uemoto, S, Terasaki, PI. Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. Transplantation. 2014; 98: 1105-11.
Taniguchi, M, Rebellato, LM, Cai, J, Hopfield, J, Briley, KP, Haisch, CE, Catrou, PG, Bolin, P, Parker, K, Kendrick, WT, Kendrick, SA, Harland, RC, Terasaki, PI. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant. 2013;13:2577-89.
Taniguchi, M, Kawabata, M. KIR3DL1/S1 genotypes and KIR2DS4 allelic variants in the AB KIR genotypes are associated with Plasmodium-positive individuals in malaria infection. Immunogenetics. 2009;61:717-30.